Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3585-3599
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3585
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3585
Figure 3 Insulin-like growth factor 2 activated the IGF1R signaling in gastrointestinal stromal tumors cells.
A: Quantitative reverse transcriptase PCR assay of IGF1R mRNA expression in gastrointestinal stromal tumors (GIST) 882 and GIST-T1 cells after OE-insulin-like growth factor 2 (IGF2) or sh-IGF2 transfection; B: Detection of protein levels (IGF1R, p-IGF1R, PI3K, AKT, and p-AKT) involved in the PI3K/AKT in OE-IGF2 or sh-IGF2 transfected-GIST-T1 cells by western blot assay; C: Detection of protein levels (IGF1R, p-IGF1R, PI3K, AKT, and p-AKT) involved in the PI3K/AKT in GIST-T1 cells after sh-IGF2 and OE-IGF2R transfection by western blot assay. bP < 0.01; cP < 0.001.
- Citation: Li DG, Jiang JP, Chen FY, Wu W, Fu J, Wang GH, Li YB. Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors. World J Gastrointest Oncol 2024; 16(8): 3585-3599
- URL: https://www.wjgnet.com/1948-5204/full/v16/i8/3585.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i8.3585